blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP4382135

EP4382135 - CANCER-SPECIFIC TRANS-SPLICING RIBOZYME AS GENE THERAPY PRODUCT COMBINED WITH RADIOTHERAPY [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  10.05.2024
Database last updated on 29.10.2024
FormerThe international publication has been made
Status updated on  10.02.2023
Most recent event   Tooltip11.10.2024Change: Validation statespublished on 13.11.2024 [2024/46]
11.10.2024Change - extension statespublished on 13.11.2024 [2024/46]
Applicant(s)For all designated states
RZNOMICS INC.
327, Software ICT Building
Dankook University
152, Jukjeon-ro
Suji-gu
Yongin-si, Gyeonggi-do 16890 / KR
[2024/24]
Inventor(s)01 / LEE, Seong-Wook
Seoul 02780 / KR
02 / HAN, Seung Ryul
Yongin-si, Gyeonggi-do 16919 / KR
03 / PARK, Hee Chul
Seoul 06355 / KR
04 / CHOI, Changhoon
Seongnam-si, Gyeonggi-do 13600 / KR
05 / SHIN, Sungwon
Seoul 05841 / KR
 [2024/24]
Representative(s)De Clercq & Partners
Edgard Gevaertdreef 10a
9830 Sint-Martens-Latem / BE
[2024/24]
Application number, filing date22853581.108.08.2022
[2024/24]
WO2022KR11774
Priority number, dateKR2021010381406.08.2021         Original published format: KR 20210103814
KR2022009808905.08.2022         Original published format: KR 20220098089
[2024/24]
Filing languageKO
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2023014206
Date:09.02.2023
Language:KO
[2023/06]
Type: A1 Application with search report 
No.:EP4382135
Date:12.06.2024
Language:EN
[2024/24]
Search report(s)International search report - published on:KR09.02.2023
ClassificationIPC:A61K48/00, A61K31/7105, A61P35/00, C12N15/113
[2024/24]
CPC:
A61K48/005 (EP); A61P35/00 (EP); C12N15/113 (EP);
C12N2710/10343 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2024/24]
TitleGerman:KREBSSPEZIFISCHES TRANSSPLEISSENDES RIBOZYM ALS GENTHERAPIEPRODUKT IN KOMBINATION MIT STRAHLENTHERAPIE[2024/24]
English:CANCER-SPECIFIC TRANS-SPLICING RIBOZYME AS GENE THERAPY PRODUCT COMBINED WITH RADIOTHERAPY[2024/24]
French:RIBOZYME DE TRANS-ÉPISSAGE SPÉCIFIQUE AU CANCER EN TANT QUE PRODUIT DE THÉRAPIE GÉNIQUE COMBINÉ À UNE RADIOTHÉRAPIE[2024/24]
Entry into regional phase06.03.2024Translation filed 
06.03.2024National basic fee paid 
06.03.2024Search fee paid 
06.03.2024Designation fee(s) paid 
06.03.2024Examination fee paid 
Examination procedure06.03.2024Examination requested  [2024/24]
Fees paidRenewal fee
27.08.2024Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A]WO2015194853  (KOREA ATOMIC ENERGY RES [KR]);
 [DA]KR20160038674  (UNIV DANKOOK IACF [KR]);
 [A]KR20190007488  (REGENERON PHARMA [US]);
 [Y]KR20200102943  (RZNOMICS INC [KR], et al);
 [A]KR102195221B  (SEOUL NAT UNIV R&DB FOUNDATION [KR]);
by applicantKR20160038674
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.